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Background: Benfotiamine (BFT) is a synthetic thiamine precursor with high bioavailability. It is efﬁcient in
treating complications of type 2 diabetes and has beneﬁcial effects in mouse models of neurodegenerative dis-
eases. The mechanism of action of BFT remains unknown, though it is sometimes suggested that it may be linked
to increased thiamine diphosphate (ThDP) coenzyme function.
Methods: We used a mouse neuroblastoma cell line (Neuro2a) grown in thiamine-restricted medium. The cells
were stressed by exposure to paraquat (PQ) or amyloid β1-42 peptide in the presence or absence of BFT and the cell
survival was measured using the MTT method. In each case, BFT was compared with sulbutiamine (SuBT), an
unrelated thiamine precursor, and thiamine. Metabolites of BFT were determined by HPLC and mass
spectrometry.
Results: At 50 μM, BFT protects the cells against PQ and amyloid β1-42 peptide-induced toxicity with the same
efﬁcacy. Protective effects were also observed with SuBT and with higher concentrations of thiamine. The main
metabolites of BFT were thiamine and S-benzoylthiamine (S-BT). Treatment with both precursors induces a strong
increase in intracellular content of thiamine. Protective effects of BFT and SuBT are directly related to thiamine
(but not ThDP) levels in Neuro2a cells.
Conclusions: BFT, SuBT and thiamine all protect the cells against oxidative stress, suggesting an antioxidant effect
of thiamine. Our results are not in favor of a direct ROS scavenging effect of thiamine but rather an indirect effect
possibly mediated by some antioxidant signaling pathway. It is however not clear whether this effect is due to
thiamine itself, its thiol form or an unknown metabolite.
General signiﬁcance: Our results suggest a role of thiamine in protection against oxidative stress, independent of
the coenzyme function of thiamine diphosphate.1. Introduction
Thiamine (vitamin B1) is essential for the nervous system. It is the
precursor of thiamine diphosphate (ThDP), an important coenzyme for
transketolase, pyruvate dehydrogenase and 2-oxoglutarate dehydroge-
nase [1]. It is thus essential for brain energy metabolism. ThDP is formed
by pyrophosphorylation of thiamine, a reaction catalyzed by thiamine
pyrophosphokinase (TPK). Thiamine monophosphate (ThMP) is also
found in the brain as a minor thiamine compound. It is formed by
dephosporylation of ThDP, but it has no known speciﬁc role.t; BFT, benfotiamine; FBS, fetal b
ThDP, thiamine diphosphate; ThM
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Thiamine deﬁciency leads to severe lesions of the nervous system.
Thiamine deﬁciency disorders are complex and can adopt various forms
[1]. While nutritional thiamine deﬁciency often leads to polyneuritic
syndromes such as beriberi, alcohol-induced thiamine deﬁciency leads to
Wernicke's encephalopathy, with potential fatal outcome, and Korsakoff's
syndrome, a memory disorder [4]. When no irreversible brain lesions are
present, thiamine deﬁciency responds well to treatment with orally
administered thiamine. However, the intestinal absorption of thiamine,
which requires speciﬁc transporters, is rate-limiting [5]. For this reason,ovine serum; O-BT, O-benzoylthiamine; S-BT, S-benzoylthiamine; PQ, paraquat;
P, thiamine monophosphate; TPK, thiamine pyrophosphokinase.
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Presently, the most widely used is benfotiamine (BFT). Initially, BFT was
used to increase blood thiamine levels in patients suffering from thiamine
deﬁciency. It was later shown to prevent experimental diabetic retinop-
athy [6]. More recently, BFT was shown to have powerful beneﬁcial ef-
fects in mouse models of neurodegenerative diseases [7, 8]. An
interesting point is that in both studies, BFT did not lead to increased
levels of ThDP in the brain: only thiamine slightly increased. This
observation is in agreement with at least two other studies in which BFT
treatment did not lead to increased brain ThDP content, while it was
increased in blood and liver [9, 10]. In the latter study [10], thiamine and
BFT prevented predator stress-induced suppression of neurogenesis.
Hence, it is now well documented that BFT can have powerful neuro-
protective and anti-stress effects in the rodent brain, but they do not seem
to be mediated by stimulation of ThDP-dependent enzymes.
In a mouse model of tauopathy [8], long-term treatment with BFT not
only reduced hyperphosphorylated tau in brain but also increased the
life-span of the animals, prevented death of spinal cord motor neurons
and decreased oxidative stress and inﬂammation. However, brain
transketolase activity was only slightly increased and α-ketoglutarate
dehydrogenase activity was not signiﬁcantly changed, in agreement with
unaffected ThDP levels. The authors suggested amodel in which products
of BFT metabolism such as S-benzoylthiamine (S-BT) or O-benzoylthi-
amine (O-BT) (Fig. 1) would activate the Nrf2-antioxidant response
element (ARE) signaling pathway, critical for the activation of genes
involved in the elimination of reactive oxygen species (ROS) [11].
This hypothesis was based on three ﬁndings:
1) In transgenic mice, BFT treatment increases the expression of some
oxidative stress-protective enzymes known to be under the control of
Nrf2.Fig. 1. Chemical structures of thiamine, thiochrome, benfotiamine, sulbutiamine, S-b
the isobutyrate group (substituted by a H in thiamine disulﬁde) of SuBT is in blue,
22) BFT, S-BT and O-BT activate the Nrf2 transcription pathway in
cultured cells, but concentrations as high as 100 μMwere required for
full activation.
3) Docking studies with Keap-1, a protein sequestering Nrf-2, suggest
that BFT, S-BT and O-BT could bind to Keap-1 with high afﬁnity,
thereby releasing Nrf2 and allowing its transfer to the nucleus, pro-
moting its transcription factor activity.
Though these data suggest that BFT, S-BT and O-BT can indeed
activate the Nrf2/ARE pathway in vitro, there is so far no evidence that
signiﬁcant amounts of these compounds can reach the brain parenchyma,
even when the animals are treated with high doses of BFT.
It is generally agreed upon that BFT, when taken orally, is dephos-
phorylated to S-BT by the alkaline phosphatases of the intestinal
epithelium. This is why oral administration of BFT is more efﬁcient than
parenteral routes. The lipophilic S-BT can then diffuse through the
epithelium and reach the blood stream. It is not known, however, what
concentrations of S-BT could be present in the blood and what could be
its half-life in this compartment. What is clearly demonstrated is that oral
treatment with BFT strongly increases blood thiamine levels in mice, the
maximum being reached two hours after gavage [9]. This suggests that
most of the S-BT that reaches the blood stream is converted to free
thiamine after a few hours. In the brain, there is a slight increase in
thiamine content but ThDP does not increase signiﬁcantly, in line with
data obtained in mouse models of stress and neurodegenerative diseases.
Taken together, those data strongly suggest that the effects of BFT
treatment are not linked to an activation of ThDP-dependent enzymes
and subsequent boosting of brain energy metabolism. As the most con-
spicuous effect of BFT treatment is a strong increase in blood thiamine
levels, it is tempting to assume that the neuroprotective effects of BFT
involve free thiamine rather than the coenzyme ThDP. In theenzoylthiamine and O-benzoylthiamine. The thiamine sulfur is indicated in red,
and the phosphoryl group of benfotiamine is in green.
M. Sambon et al. Heliyon 5 (2019) e01710above-mentioned study [8], treatment with free thiamine was not found
to be neuroprotective, but other studies [12, 13] demonstrated anti-stress
and anti-depressive effects of BFT and thiamine in mice and an
involvement of glycogen synthase kinase-3β was suggested.
In any event, the mechanisms underlying the neuroprotective effects
of thiamine and its precursors remain largely enigmatic, both concerning
the derivative(s) responsible for these effects and the targets involved. In
the present study, we tackle the problem by studying the metabolization
of BFT in vitro, using cultures of neuroblastoma (Neuro2a) cells. We
developed a UHPLC-ESI mass spectrometry method to identify the major
metabolites of BFT. We then investigated the protective effects of BFT on
paraquat (PQ)-induced cell death, a model of oxidative stress.
To clarify the possible roles of BFT metabolites in cell protection, we
systematically compared the effects of BFT with those of thiamine and
sulbutiamine (SuBT, Fig. 1), a disulﬁde derivative with a different
pharmacological proﬁle [9]. SuBT is a dimer with both thiaminemoieties
linked by a disulﬁde bridge. An isobutyryl group, increasing the hydro-
phobic character of the molecule, esteriﬁes both moieties. SuBT freely
diffuses through biological membranes and is rapidly converted to
thiamine in the cytoplasm. It is highly effective in increasing blood and
tissue thiamine levels when administered to rats [14, 15]. In humans,
SuBT was reported to be effective against asthenia and other fatigue
syndromes [16, 17].
Our results suggest that BFT exerts cell-protective effects against
oxidative stress and that these effects are mediated by thiamine or a
presently unknown thiamine metabolite, independently of the coenzyme
function of ThDP. Our results are not in favor of a speciﬁc BFT metabolite
being responsible for these effects.
2. Results
As cell culture media generally contain a high thiamine concentration
(approximately 10 μM) we ﬁrst adapted our cells for 7 days to a low-
thiamine medium as previously described [18, 19]. The culture me-
dium is devoid of the vitamin and the only source of thiamine is fetal
bovine serum (FBS) with a concentration of about 100 nM. The ﬁnal
thiamine concentration in the growth medium was thus 10 nM. This
amount of thiamine is sufﬁcient for normal growth of Neuro2a cells. Thus
our “thiamine-restricted” medium does not cause any deﬁciency of the
vitamin, though the total thiamine content of the cells was about 10-fold
lower than when the cells were grown in thiamine-rich (10 μM) medium
[18, 19].Fig. 2. Intracellular content (pmol/mg of protein) of thiamine (A, B, C) and ThDP (D,
(A, D), BFT (B, E) or 0 (control), 0.5, 5 and 25 μM SuBT (C, F). As the medium contain
DMEM medium at t ¼ 0 in all samples. Please note the logarithmic scales in A, B an
3Neuro2a cells grown for 7 days in thiamine-restricted medium were
exposed to different concentrations of thiamine, SuBT and BFT for up to 6
h in the same medium but without FBS, and the intracellular thiamine
and ThDP contents were estimated (Fig. 2). For simpliﬁcation the content
in the minor ThMP derivative is not indicated here. The uptake of thia-
mine, which can only enter the cells through speciﬁc transporters, is
limited by the low catalytic turnover of these transporters.
BFT is a particular case as it is negatively charged because of the
phosphate group. It is thought that it must be dephosphorylated to S-BT
by extracellular phosphatases; the lipophilic S-BT may then diffuse into
the cells. The slow hydrolysis of BFT by exogenous phosphatases (pre-
sumably membrane-bound ectophosphatases) explains that it takes more
than two hours of exposure before the cell content of thiamine increases
signiﬁcantly.
In contrast, when the lipophilic SuBT is used, the maximum intra-
cellular concentration of thiamine is reached after two hours and little
increase is observed after longer times. Note that SuBT is always used at
half the molar concentrations of the other derivatives as it yields two
molecules of thiamine (Fig. 1). It is obvious that the lipophilic SuBT is by
far the most efﬁcient in increasing cell thiamine content as it can directly
diffuse through the cell membranes.
Concerning intracellular ThDP content, a slow but substantial in-
crease is observed (from 15 - 20 to nearly 100 pmol/mg protein), but the
results are not very different when free thiamine or the two precursors
are used. This would be in line with the assumption that the rate-limiting
factor for ThDP formation is the activity of the enzyme TPK, which has a
low Km (107-106 M) for thiamine. Therefore, the rate of ThDP syn-
thesis should not increase substantially when the intracellular concen-
tration of free thiamine increases.
Data from Fig. 2B can be interpreted if we assume that, in serum-free
medium, BFT is only slowly hydrolyzed to S-BT by phosphatases bound
to cell membranes. We suspected that BFT hydrolysis might become
faster in the presence of serum, which might also contain phosphatases.
Thus, we incubated the cells with 50 μM BFT in the presence or in the
absence of 10% FBS (Fig. 3 and Fig. 4). As shown in Fig. 3A, there is a
very strong accumulation of thiamine in the presence of FBS after 1 h,
while in the absence of serum, the accumulation of intracellular thiamine
was much smaller, even after several hours (Fig. 2B). However, this
accumulation does not lead to a signiﬁcant increase in the coenzyme
ThDP or in ThMP.
This effect of FBS is speciﬁc for BFT. Indeed, in the presence of
thiamine (10 μM) or SuBT (5 μM) no effect of FBS on intracellularE, F) as a function of time after addition of 0 (control), 1, 10 and 50 μM thiamine
ed no serum, a small amount of thiamine (10 nM) was added to the thiamine-free
d C. (Mean  SD, n-3).
Fig. 3. Effect of FBS on the intracellular content of thiamine, BFT and thio-
chrome after incubation of Neuro2a cells with BFT for one hour in the absence
or the presence of 10% FBS. (A) Intracellular content of thiamine, ThMP and
ThDP determined by HPLC (mean  SD, n ¼ 3). (B) Intracellular content of BFT,
S-BT and thiochrome determined by mass spectrometry (Mean  SD, n ¼ 3;
AUC, area under curve).
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With our HPLCmethod, which is based on the ﬂuorescent detection of
thiochrome derivatives, we can detect only compounds that can be
directly oxidized into ﬂuorescent thiochromes. This is not the case of
BFT, S-BT or other potential metabolites of these compounds with anFig. 4. Effect of FBS on the intracellular content of thiamine derivatives after incubat
(10 μM) or SuBT (5 μM) for 2 h. Statistical analysis by two-way ANOVA followed by
¼ 4).
4open thiazolium ring. Therefore, we used mass spectrometry to detect
such metabolites in the cells after treatment with BFT (Fig. 3B). After
incubationwith BFT (50 μM) for 1 h, the major metabolite detected in the
cells (in addition to thiamine) was S-BT. Only minor amounts of thio-
chrome were detected. Moreover, the amount of thiochrome was not
signiﬁcantly higher than in controls. This suggests that thiochrome may
be formed intracellularly in small amounts, but this is not dependent on
treatment with BFT. Even if we did not quantify each metabolite using a
calibration curve in those experiments, it seems that the most abundant
metabolite of BFT is S-BT and that the presence of FBS strongly increases
the formation and entry of S-BT into the cells, where thiamine is formed
rapidly. This effect can be due either to the presence of phosphatases in
the FBS or the induction of ectophosphatases by the cells. In order to
distinguish between these two possibilities, BFT was incubated in the
presence of FBS (without cells) and we quantiﬁed its metabolites as a
function of time (Fig. 5). It can be seen that BFT rapidly disappears while
a simultaneous appearance of S-BT is observed after 60 min. The amount
of BFT drops from 50 to 20 μM, while 30 μM S-BT is formed, suggesting
that within 1 h about 60% of the BFT is hydrolyzed by phosphatases
present in the serum. However, when the incubation is prolonged from 1
to 6 h, the concentration of S-BT slowly decreases while free thiamine is
formed.
Two main conclusions can be drawn from these data:
1) When BFT is added to Neuro2a cells cultured in thiamine-restricted
medium, the ﬁrst metabolite detected in the cells is S-BT. The
appearance of S-BT is faster when the medium contains 10% FBS.
Under these conditions, 50% of BFT is hydrolyzed in less than 60 min.
Thus, BFT appears to be a good substrate for phosphatases present in
FBS. It must be emphasized that FBS is at a concentration of 10% in
the culture medium. We can thus expect that in the blood these
transformations will be even much more rapid and it is doubtful that
signiﬁcant concentrations of BFT are reached in blood after BFT
administration.
2) A second metabolite of BFT is thiamine. In Neuro2a cells, it is plau-
sible that, after freely diffusing into the cytoplasm, S-BT is converted
to the thiol form of thiamine through the action of endogenous thi-
oesterases. At an intracellular pH close to neutral, the thiol form is
quickly converted to thiamine. Unexpectedly, we found that in the
absence of cells, S-BT is also unstable and is slowly converted toion of Neuro2a cells in the presence of thiamine (10 nM), thiamine (10 μM), BFT
Bonferroni's post-hoc comparisons test: **p < 0.01, ***p < 0.001 (Mean  SD, n
Fig. 5. Time-dependence of the concentrations of BFT, S-BT and thiamine in a
culture medium supplemented with 50 μM BFT (without thiamine) and 10 %
FBS. (Mean  SD, n ¼ 3).
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serum. After oral administration, BFT will be hydrolyzed by intestinal
alkaline phosphatases to S-BT, which will be absorbed by the intes-
tinal epithelium. It is probable that a large proportion of S-BT will be
transformed to thiamine already within the epithelial cells and
transported into the blood. Even if relatively large amounts of S-BT
would appear in the blood, they should be converted to thiamine by
thioesterases. S-BTmay also be transformed in the liver. It is therefore
not likely that large amounts of S-BT will be present in the blood. If
signiﬁcant amounts were present shortly after BFT administration,
they would probably disappear within a short time. Note, that is was
reported [20] that S-BT is unstable and that it can be spontaneously
converted to O-BT at pH  7.
In a second part of this study, we wanted to compare the protective
effects of thiamine and its precursors (BFT and SuBT) against PQ toxicity
in Neuro2a cells. The herbicide PQ is known to be toxic to many cell
types, including neuronal cells, through production of ROS [21, 22].
When Neuro2a cells were grown in thiamine-restricted mediumFig. 6. Protection of thiamine, BFT and SuBT against PQ-induced cell death. A) PQ
μM) and SuBT (25 μM) on cell survival after exposure (24 h) to 0.25 mM PQ (mean 
4). D-F) Effect of various concentrations of thiamine, BFT and SuBT on the survival
5containing 10% FBS, a 24 h exposure to PQ in the same medium caused a
dose-dependent decrease of cell viability with an IC50 of 0.32 0.04 mM
(Fig. 6A). To study the possible protective effects of thiamine and its
precursors, the cells were ﬁrst exposed to 50 μM thiamine, BFT or SuBT
for 1 h prior to addition of 0.25mMPQ and incubation for 24 h. As shown
in Fig. 6B, the cell survival rate was 50–60% after PQ exposure. The
addition of thiamine (50 μM) to the medium had no signiﬁcant effect on
cell survival. In contrast, addition of BFT (50 μM) signiﬁcantly improved
survival. With SuBT (25 μM), a signiﬁcant protective effect was also
observed.
As PQ is known to be an inducer of oxidative stress, it seemed plau-
sible that the protective effects of thiamine precursors could be linked to
an antioxidant effect. We therefore measured the level of protein
carbonylation, a well-known indicator of oxidative damage, in Neuro2a
cells in our experimental conditions (Fig. 6C). As expected, exposure of
the cells to PQ increased protein carbonylation and this was relieved by
either BFT (50 μM) or SuBT (25 μM). Though there seemed to be an effect
of thiamine (50 μM), it was not signiﬁcant. This suggests that the two
precursors exert antioxidant effects in Neuro2a cells exposed to PQ.
We then studied the effects of increasing concentrations of thiamine,
BFT and SuBT on cell survival in the presence of PQ. As shown in Fig. 6D,
thiamine exerted little protection at low concentrations but a signiﬁcant
protective effect was observed at 100 μM or higher. This is probably
linked to thiamine uptake through a low-afﬁnity thiamine transporter
that was previously shown to be present in Neuro2a cells [18]. With BFT
(Fig. 6E), maximal protection was observed at 25 μM, and a similar
protective effect was observed with the same concentration of SuBT
(Fig. 6F), but remember it is a dimer. This is an important result, as
metabolites such as S-BT or O-BT can only be formed from BFT, but not
from the disulﬁde SuBT or from thiamine. The only common metabolite
of BFT and SuBT is thiamine, suggesting that the pharmacologically
efﬁcient compound is thiamine or possibly an unknown metabolite of
thiamine. We considered the possibility that part of the intracellular
thiamine might be oxidized to thiochrome in the presence of PQ.
Treatment with PQ or the combination of PQ and thiamine compounds
had no effect on intracellular thiochrome content (data not shown),
suggesting that this compound is not involved in the cell-protective
effects.
The results presented in Fig. 2 show that when Neuro2a cells grown in
thiamine-restricted mediumwere exposed to thiamine, BFT or SuBT for 6
h, the intracellular concentrations of both thiamine and ThDP increased.dose-survival curve (mean  SD, n ¼ 3). B) Effect of thiamine (50 μM), BFT (50
SD, n ¼ 3). C) Protein carbonylation under the same conditions (mean  SD, n ¼
of Neuro2a cell after exposure to PQ. (Mean  SD, n ¼ 3).
Fig. 8. Correlation between cell survival (%) and intracellular thiamine and
ThDP concentrations after 25 h in the absence or presence of various thiamine
precursors and in the presence of PQ (0.25 mM) as described in legend to Fig. 5.
Pearson's correlation regression analysis revealed a signiﬁcant correlation with
thiamine (p ¼ 0.0267, r ¼ 0.9204, n ¼ 5) but not with ThDP (p ¼ 0.1212, r ¼
0.7781, n ¼ 5). Both slopes were signiﬁcantly different (p ¼ 0.0144).
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be linked to an increase in either thiamine or ThDP contents of the cells.
We therefore measured the intracellular contents of thiamine and ThDP
after incubation in a medium supplemented with 10% FBS after 1 and 25
h (corresponding to the time points of the experiments in Fig. 6). As
shown in Fig. 7, the two precursors were much more efﬁcient than
thiamine in raising intracellular thiamine content, both after 1 h and 25
h. Note that the strong increase observed after 1 h in the presence of 50
μM BFT is linked to the presence of serum in the medium: serum phos-
phatases hydrolyze BFT, releasing the lipophilic S-BT that enters the cells
where it is converted to thiamine (see above, Fig. 4A).
However, the increase of intracellular ThDP in the presence of BFT or
SuBT was not signiﬁcantly higher than when the cells were exposed to
free thiamine. This suggests that the protective effects of BFT and SuBT
are not linked to increased contents of the coenzyme ThDP in the cells. In
order to test this hypothesis, we expressed the cell survival as a function
of the intracellular thiamine and ThDP concentrations obtained with
various precursors (Fig. 8). A signiﬁcant correlation was obtained be-
tween cell survival and intracellular thiamine concentration but not with
intracellular ThDP concentration. This is in agreement with many ob-
servations showing that treatment of mice with BFT has many beneﬁcial
effects in the central nervous system, but does not cause any increase in
brain ThDP levels [7, 8, 9, 10].
It should be emphasized that ThDP concentrations increase with
thiamine concentrations as the latter is the precursor of the former
through the reaction Thiamineþ ATP⇆ ThDPþ AMP, catalyzed by TPK.
In order to further investigate the possibility that the protective ef-
fects of BFT are due to increased intracellular thiamine rather than ThDP,
we measured the effect of pyrithiamine on the protection of BFT against
PQ-induced cell death (Fig. 9). Pyrithiamine is a potent inhibitor of
thiamine transport [18], but it also competitively inhibits TPK [23] while
also serving as a substrate for the enzyme. However, pyrithiamine
diphosphate cannot act a coenzyme for ThDP-dependent enzymes. It is
therefore a very powerful thiamine antimetabolite [24]. When the cells
were exposed to pyrithiamine, intracellular ThDP levels dramaticallyFig. 7. Effect of thiamine, BFT and SuBT on intracellular thiamine and ThDP after 1 a
*, p < 0.05; **, p < 0.01; ***, p < 0.001.
6decreased, becoming undetectable after 24 h (Fig. 9B). We have previ-
ously shown (using the thiamine transport inhibitor amprolium instead
of pyrithiamine) that under such harsh condition Neuro2a cell start to die
after 48 h [19]. In the presence of PQ and BFT, pyrithiamine strongly
decreased intracellular ThDP levels (Fig. 9B), while thiamine levels were
increased (Fig. 9A), in agreement with an inhibition of TPK leading to an
accumulation of free thiamine. The fact that ThDP levels are higher in the
presence of BFT and pyrithiamine than in controls is probably due to a
competition between intracellular thiamine and pyrithiamine for TPK.
However, it can be seen that BFT was nearly as protective in the presencend 25 h. One-way ANOVA followed by Sidak's multiple comparisons test (n ¼ 3):
Fig. 9. Effect of pyrithiamine on the intracellular content
of thiamine (A) and ThDP (B) and cell survival (C) in the
presence of PQ in Neuro2a cells. The cells were incubated
in the presence of BFT and or pyrithiamine (PT) at 25 μM
for 25 h at 37 C in 6-well plates. PQ (0.25 mM) was
added 1 h after addition of pyrithiamine or BFT. Statis-
tical analysis were made by one-way ANOVA (p <
0.0001) followed by Sidak's multiple comparisons test (n
¼ 6): *, p < 0.05; **, p < 0.01; ***, p < 0.001 (Blue,
comparison with control; red, comparison with PQ).
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does not allow us to completely exclude the possibility that the protective
effects of BFT are due to the coenzyme ThDP, this appears to be unlikely.
We wanted to test another kind of stress, and more relevant to Alz-
heimer's disease than PQ. It is indeed well known that soluble Aβ, and in
particular the Aβ1-42 peptide is toxic for cells. Indeed, at a concentration
>1 μM it decreases cell survival in our Neuro2a cell line (Fig. 10A). These
concentrations are in agreement with published data [25, 26, 27]. The
Aβ1-42-induced decrease in cell survival was antagonized by thiamine,
BFT and SuBT (Fig. 10B). Thiamine was already active at 50 μM, while in
PQ-induced decreased cell survival a concentration higher than 50 μM
thiamine was required (Fig. 6D).
A plausible interpretation of the above results is that the protective
effects of BFT and SuBT against PQ or Aβ1-42 toxicity are linked to the
important intracellular accumulation of thiamine. How could thiamine
relieve the damaging effects of ROS ? It could have either direct or in-
direct antioxidant effects.
Direct antioxidant effects should be considered, as it has been re-
ported [28, 29] that thiamine and ThDP have antioxidant or radical
scavenging activities in vitro. Using a superoxide-generating system, Okai
et al. [29], showed that thiamine and ThDP exerted suppressive effects on
superoxide production, with IC50 values around 158 μM for thiamine and
56 μM for ThDP. If intracellular thiamine or ThDP concentrations of this
order could be reached in our cells after treatment with thiamine pre-
cursors, the possibility of a protection against PQ by a direct reaction
between thiamine and superoxide should be considered. As shown in
Fig. 11A, the amount of intracellular thiamine after treatment with 50 μMFig. 10. Protection of Neuro2a cells by thiamine, BFT and SuBT against Aβ1-42-
induced cell death. A) Effect of increasing concentrations of Aβ1-42 on the sur-
vival rate of Neuro2a cells for 24h in thiamine-restricted medium (***, p <
0,001; mean  SD; n ¼ 3). B) Effect of thiamine (50 μM), BFT (50 μM) and SuBT
(25 μM) on the survival rate of Neuro2a cells exposed to 10 μM Aβ1-42 for 24h in
thiamine-restricted medium (*, p < 0.05). Each column represents the mean 
SD (n ¼ 3 with 3 replicates each time).
7BFT can reach approximately 550 pmol/mg of protein. If the cell volume
is 4.5 μl per mg of protein [18], the intracellular concentration of thia-
mine would be 120 μM, which might signiﬁcantly reduce the amount of
superoxide in Neuro2a cells. However, we ﬁnd that intracellular thia-
mine is not decreased by exposure to PQ (Fig. 11A), suggesting that no
appreciable amounts of thiamine have reacted with ROS produced in the
presence of PQ. On the other hand, it was suggested [28] that the
oxidation of thiamine by ROS mainly yields thiochrome. We detected no
increase in thiochrome production by our cells after exposure to PQ (data
not shown).
Concerning ThDP, Okai et al. [29], reported that it was more efﬁcientFig. 11. Effect of PQ on thiamine and ThDP content in Neuro2a cells. Neuro2a
cells were incubated with or without PQ (0.25 mM) for 24 h at 37 C in 6-well
plates in the absence of added thiamine, or in the presence of 50 μM thiamine or
BFT. None of the differences between control and PQ were signiﬁcant.
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μM. According to data shown in Fig. 11B, the intracellular ThDP con-
centration after BFT treatment would reach 25 μM. However, the major
part of it is bound to apoenzymes [30] and, again, exposure to PQ had no
signiﬁcant effect on intracellular ThDP content (Fig. 11B). We conclude
that the direct antixoxidant effects of thiamine and ThDP contribute at
best to a small extent to the protection exerted by thiamine precursors on
PQ toxicity.
We therefore considered that the protective effects of BFT and SuBT
were mainly linked to indirect mechanisms. Activation of the Nrf2/ARE
pathway has been extensively studied as a mechanism involved in neu-
roprotection [31]. Nrf2 is a transcription factor that can be transferred
from the cytosol to the nucleus when ROS or electrophilic compounds are
present in the cells. In the nucleus, Nrf2 binds to a promotor element
called the antioxidant response element (ARE). This activates the
expression of a battery of genes involved in protection against oxidative
stress. Here we used a luciferase reporter stable cell line (3T3 cells) to test
the effects of thiamine and its precursors on Nrf2 activation. In the
presence of luciferase substrates, luminescence is induced in the cells
when Nrf2 binds to ARE. We ﬁrst demonstrated that, in 3T3 cells as in
Neuro2a cells, thiamine precursors protect against PQ toxicity. As shown
in Fig. 12A, 24h exposure to 0.25 mM PQ decreased 3T3 cell viability by
40%, and this was relieved in the presence of 50 μM BFT or 25 μM SuBT.
We then measured the luminescence in the presence of PQ, thiamine
precursors and, as a positive control, tBHQ. The latter is an electrophilic
compound which is a prototypical Nrf2 stabilizer [32]. As expected,
tBHQ strongly increased the luminescence of the cells (400%) (Fig. 12B).
tBHQ also protected against PQ toxicity in both 3T3 and Neuro2a cells
(not shown), indicating that the Nrf2/ARE pathway can be activated to
protect these cells against oxidative stress. Exposure to 0.25 mM PQ
induced a modest (70–80%) increase in luminescence, in line with the
known ability of ROS production to activate the Nrf2/ARE pathway [31].
However, PQ was much less effective than tBHQ, suggesting that the8Nrf2/ARE pathway is not fully activated by exposure to PQ. As shown in
Fig. 12C, incubation of 3T3 cells with 50 μM BFT or 25 μМ SuBT for 24 h
also caused a modest but signiﬁcant increase in luminescence (about
50%). This is in agreement with a recent study [8] showing a modest
activation of the Nrf2/ARE pathway by 50 μM BFT in a human neuro-
blastoma reporter cell line; full activation required a concentration of
100 μM.
We can conclude from these data that in 3T3 cells, exposure to either
PQ (0.25 mM) of BFT (50 μM) can activate the Nrf2/ARE pathway to
some extent, but this is only a weak stimulation compared to the effect of
tBHQ. Moreover, data from Fig. 12D show that when 3T3 cells are
exposed to PQ, the simultaneous presence of thiamine, BFT or SuBT fails
to induce a further increase in luminescence. This suggests that, under
our conditions, the protective effects of thiamine and its precursors
against PQ toxicity are not mainly linked to the activation of the Nrf2/
ARE pathway. This is in line with the fact that the main effect of BFT and
SuBT is to increase the intracellular concentration of thiamine. In
contrast to tBHQ, thiamine has no marked electrophilic properties and is
thus not expected to cause an important stabilization of Nrf2.
3. Discussion
Several animal and human studies have demonstrated that treatment
with thiamine and precursors with high bioavailability has beneﬁcial
effects in various pathological conditions such as complications of type II
diabetes [6], mouse models of depression related to chronic stress [10,
12] and models of Alzheimer's disease [7] and tauopathies [8]. Most of
these investigations were performed using BFT as the thiamine precursor,
and its effectiveness has been demonstrated both in vivo and in cellular
models. However, the molecular mechanisms underlying the neuro-
protective effects of thiamine and BFT remain unclear. A ﬁrst possible
explanation is that the increase in thiamine content of tissues after
treatment with high doses of thiamine or BFT increases the production ofFig. 12. Effects of tBHQ, PQ, thiamine BFT and SuBT on
viability and luminescence of a Nrf2/ARE luciferase re-
porter 3T3 stable cell line. A) Protective effects of thia-
mine, BFT and SuBT against PQ-induced cell death. B)
Effects of PQ and tBHQ on Nrf2/ARE activation (24-h
incubation). C) Effects of thiamine, BFT and SuBT on
Nrf2/ARE activation (24 h incubation). D) Combination
of PQ and thiamine, BFT and SuBT on Nrf2/ARE acti-
vation. Thiamine and precursors were added 1 h prior to
PQ. One-way ANOVA followed by Dunnett's multiple
comparisons test (B and C). One-way ANOVA followed
by Tukey's multiple comparisons test (A and D).
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considered that the only biologically active form of thiamine is ThDP.
The harmful effects of thiamine deﬁciency in the brain are generally
ascribed to reduced activity of ThDP-dependent enzymes such as 2-oxo-
glutarate dehydrogenase complex. This causes an impairment of the
citric acid cycle and respiratory chain activity, with increased production
of ROS and impairment of oxidative metabolism [33]. This is obviously
harmful for neurons, as their activity and survival is heavily dependent
on oxidative energy metabolism.
Although pathological features of thiamine deﬁciency may be related
— at least in part — to reduced activity of ThDP-dependent enzymes,
activation of these enzymes does not appear to be a satisfactory expla-
nation for the beneﬁcial effects of BFT treatment in mouse models of
neurodegeneration and other pathological syndromes. Indeed, such ef-
fects have been demonstrated in animals that were not deﬁcient in
thiamine and had normal brain levels of ThDP. Many different studies
from several laboratories have shown that administration of even high
doses (200 mg/kg) of thiamine or BFT in mice does not lead to increased
ThDP levels; only thiamine is increased by 50–100% [7, 8, 9, 10]. This
suggests that the co-enzyme function of ThDP is not substantially
enhanced in the brain after BFT treatment.
So far, no alternative mechanisms to explain the neuroprotective ef-
fects of thiamine and its precursors have been proposed. It is well
established that oral administration of BFT in mice results in a strong
increase in blood concentrations of thiamine after a few hours. In the
brain, however, the content of free thiamine increases by at best 100%
[9] and it seems unlikely that the low amount of unphosphorylated
thiamine present in the brain parenchyma could exert marked protective
effects. This raises the possibility that unidentiﬁed metabolites of thia-
mine or BFT and even SuBT might be the active neuroprotective agents.
We therefore decided to investigate BFT metabolism in a simpler in
vitro system, using cultured Neuro2a cells, that we have previously
characterized as to their thiaminemetabolism, thiamine transport system
and resistance to thiamine deﬁciency [18, 19, 30]. Several authors re-
ported protective effects of BFT in various cell types, but none of theseFig. 13. Proposed mechanism of action of BFT and SuBT. (GSH
9studies tried to identify metabolites appearing in the cells after exposure
to BFT. Antioxidant effects have been reported [34] but high concen-
trations of BFT (300 μM) were used, and the cells were grown in a
thiamine-rich medium. In this case, we are probably dealing with direct
antioxidant effects of BFT that are not related to thiamine and are not
relevant to in vivo effects: there is indeed no evidence that BFT can be
found in the blood, let alone in the brain. So far, no BFTmetabolites other
than free thiamine have been found in the blood or in the brain.
The present study is the ﬁrst to analyze the possible role of intracel-
lular metabolites of BFT and SuBT in the protection of neuroblastoma
cells against oxidative stress. A major advantage of our study above all
previous studies is that we compare the effects of thiamine, BFT (a
thioester) and SuBT (a disulﬁde). Our results show that BFT, a polar
compound, is unable to cross cell membranes and must be dephos-
phorylated by membrane-bound phosphatase (ectoenzymes) and phos-
phatases present in the serum. This reaction yields S-BT, a lipophilic
compound that easily diffuses through the membranes and accumulates
in the cytoplasm. Within a few hours, however, it is hydrolyzed to the
open thiol form of thiamine by intracellular thioesterases. This thiol form
is unstable at physiological pH and is spontaneously converted to thia-
mine. As to SuBT, it is a lipophilic compound that diffuses through the
membranes and is ﬁrst converted to thiamine disulﬁde by intracellular
esterases. The disulﬁde is then reduced (presumably by reduced gluta-
thione [35]) to the thiol form of thiamine. The pathways leading to
thiamine accumulation when Neuro2a cells are treated with either BFT
or SuBT are displayed in Fig. 13. Note that, except for thiamine, there is
only one common metabolite for BFT and SuBT, i.e. the thiol form of
thiamine. As it is quickly converted to thiamine, it is tempting to consider
that the protective effects of the precursors are due essentially to the
intracellular accumulation of thiamine. The opening of the thiamine
thiazolium ring to form the open thiol form requires alkaline condition
[35] which is not likely under physiological conditions.
Thiamine has indeed been shown to have radical-scavenging prop-
erties in vitro, but relatively high concentrations (100–200 μM) are
required [29]. However, our results suggest that the direct antioxidant, reduced glutathione; TPK, thiamine pyrophosphokinase).
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protective effects of BFT. We therefore considered the possibility that
thiamine protects against oxidative stress through indirect mechanisms.
An obvious possibility is the activation of the Nrf2/ARE pathway, which
is the master regulator of the expression of many genes involved in cell
protection against oxidative stress [31]. Tapias et al. [8] indeed reported
that this pathway was activated when cells were treated with relatively
high concentrations (>100 μM) of BFT or its putative metabolites S-BT
and O-BT. However, thiamine was ineffective. Our results show that
thiamine and its precursors only weakly activate the Nrf2/ARE pathway
and this is not sufﬁcient to explain the protective effects of BFT and SuBT.
Yet, our results strongly suggest that the cell-protective effects of
thiamine precursors are linked to indirect antioxidant effects of intra-
cellularly accumulated thiamine and possibly unknown metabolites of
thiamine or its thiol form. Identiﬁcation of the neuroprotective pathways
(other than Nrf2/ARE) activated by thiamine compounds will require
further investigations.
In conclusion, the present study shows that the widely used thiamine
precursor BFT exerts potent antioxidant and protective effects in cultured
Neuro2a cells. As similar effects are obtained with SuBT (that yields
different metabolites), it is unlikely that speciﬁc effects of BFT metabo-
lites are involved in the protective effects of BFT. Our results suggest that
cell-protective effects of thiamine precursors are most probably mediated
by thiamine or presently unidentiﬁed thiamine metabolites, indepen-
dently of the coenzyme function of ThDP.
Considering its high bioavailability in vivo, its beneﬁcial effects in
animal models of neurodegenerative diseases and its absence of toxicity,
BFT could be considered for therapeutic purposes in humans.
4. Materials and methods
4.1. Materials and reagents
Paraquat dichloride (Methyl viologen dichloride hydrate, PQ), amy-
loid-ß protein fragment 1–42 (Aβ1-42), tert-butylhydroquinone 97%
(tBHQ), benfotiamine (S-benzoylthiamine O-monophosphate, BFT),
pyrithiamine hydrobromide and thiochrome were from Sigma-Aldrich
BVBA (Overijse, Belgium). Luciferase Assay System was from Promega
Benelux BV (Leiden, The Netherlands) and luminescence was detected in
96-well plates using a Promega GloMax-Multi Detection plate reader.
Sulbutiamine (SuBT) was from Mind Nutrition (https://mindnutr
ition.com).
4.2. Cells and cell culture
After thawing, mouse neuroblastoma (Neuro2a) cells were ﬁrst
grown in DMEM medium (Biowest, Riverside, MO, US) supplemented
with 10% fetal bovine serum (FBS) (Gibco, Life Technologies Europe BV,
Merelbeke, Belgium) in a 5% CO2 humidiﬁed atmosphere at 37 C. Then
the cells were adapted to a custom-made DMEM medium dry-packed
without thiamine (Life Technologies Limited, Paisley, Scotland, UK)
and 10% fetal bovine serum (FBS) as previously described [19]. Under
these conditions, the total thiamine concentration in the medium is
around 10 nM (roughly equivalent to the one in human plasma or serum
[36], solely coming from the FBS (100 nM). This concentration is enough
to keep the cells growing normally without signs of thiamine deﬁciency.
The Nrf2/ARE luciferase reporter NIH3T3 cell line (Signosis, Gen-
tauer Molecular Products, Kampenhout, Belgium) is stably transfected
with a pTA-ARE-luciferase reporter vector, which contains 4 repeats of
ARE, upstream of a ﬁreﬂy luciferase-coding region. When Nrf2 is stabi-
lized, it goes into the nucleus where it binds to the ARE and initiates the
transcription of luciferase gene. The cells were grown in DMEM medium
and then adapted to the DMEM medium without thiamine in the pres-
ence of 10% FBS as for Neuro2a cells.104.3. Determination of thiamine derivatives by HPLC
Brieﬂy, the cells were grown in 6-well plates under various experi-
mental conditions. For the determination of thiamine derivatives, the
cells were washed three times with PBS. Then the cells were scraped in
Tris base solution (20 mM, pH 8–8.5), transferred to Eppendorf tubes and
sonicated. Cells were treated with trichloroacetic acid (TCA, 12%) to
precipitate proteins and then centrifuged at 5000 g for 15 min. The
pellet containing the proteins was dissolved in NaOH 0.8 N solution. The
amount of protein was estimated by the method of Peterson [37]. The
supernatant containing thiamine and its phosphate esters was used for
analysis by a HPLC method using a PRP-1 column (5 μm, 4.1  150 mm)
protected by a PRP-1 10 μm guard column cartridge (Sigma-Aldrich)
after extraction of TCA by 3 1.5 ml diethylether as previously described
[38]. In addition to mass spectrometry (see 4.9), thiochrome can also be
detected by this HPLC methods by injecting the samples without prior
derivatization.
4.4. Preparation of S-benzoylthiamine
S-BT was obtained from BFT through the action of alkaline phos-
phatase (Sigma-Aldrich). BFT (1 ml, 1 mM) was incubated for 1 h at 37 C
with alkaline phosphatase (100 DEA units) from bovine intestinal mu-
cosa (Sigma-Aldrich). The hydrolysis of BFT was checked by measuring
the concentration of inorganic phosphate released by a colorimetric
method [39]. The conversion yield was 75%.
4.5. Treatment of Neuro2a cells with neurotoxic agents
Neuro2a cells were cultured in thiamine-restricted DMEM medium
containing 10% FBS. To assess cell viability, they were incubated 24 h at
37 C in 96-well plates in the same medium containing various concen-
trations of either PQ or Aβ1-42. Aβ1-42 was dissolved in dimethylsulfoxide
to prepare stock solutions. Final concentrations of dimethylsulfoxide in
assay media were 0.2%. When protective effects of thiamine or its pre-
cursors were investigated, the cells were exposed to various concentra-
tions of thiamine BFT or SuBT for 1 h prior to addition of PQ or Aβ1-42.
To evaluate the inﬂuence of PQ on intracellular content of thiamine
and its phosphorylated precursors, the cells were incubated for 24 h at 37
C in 6-well plates. The cells were exposed to thiamine and its precursors
starting 1 h prior to addition of PQ.
4.6. MTT cell survival test
To assess the viability of cultured cells, we used the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma-
Aldrich) assay. MTT tetrazolium salt was dissolved in serum-free culture
medium. Neuro2a cells were incubated with or without PQ or thiamine
precursors overnight in 96-well plates. Then, the cells were incubated in
presence of MTT tetrazolium salt (0.15 mg/ml) for 3 h at 37 C. Finally,
the medium was removed and the cells were dissolved in a solution of
isopropanol and HCl (0.22 N). The absorbance was measured at 580 nm
with a Thermo Labsystem plate reader. Results were expressed in per-
centage compared to the control conditions.
4.7. Monitoring of the activation of the antioxidant response pathway in a
Nrf2/ARE luciferase reporter NIH3T3 stable cell line
Nrf2/ARE luciferase reporter NIH3T3 cells were grown into 96-well
white-wall plates overnight in an incubator at 37 C with 5% CO2.
After treatment with PQ and thiamine precursors, the cells were washed
with 100 μl of PBS and lysed by lysis buffer (Luciferase Cell Culture Lysis,
Promega) for 15 min at room temperature. Luciferase substrate (Lucif-
erase Assay System, Promega) was added in each well and after mixing,
the luminescence was measured by a luminometer (GloMax®-Multi
Detection System, Promega).
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Protein carbonyls were detected using the OxiSelect protein ﬂuoro-
metric assay (Cell Biolabs, Bio-Connect Life Sciences, TE Huissen, The
Netherlands).
4.9. Mass spectrometry (UHPLC-ESI-MS/MS)
UHPLC was performed on a 1290 Inﬁnity LC system coupled to a
6495 triple quadrupole mass spectrometer equipped with the iFunnel
technology (Agilent Technologies, Waldbronn, Germany). Chromato-
graphic separation was performed on a reverse-phase Kinetex F5 column
(2.6 μm, 100  2.1 mm ID) protected with a Security Guard Ultra F5
precolumn (both from Phenomenex, Torrance, CA, USA). The column
compartment was thermostated at 40 C. The separation was carried out
in gradient mode with mobile phase A (H2O þ 0.1 % formic acid) and B
(ACN þ 0.1% formic acid) at 0.5 ml/min. The gradient started at 2% B
and ramped to 40% B in 3 minutes. It was set at 95% B from 3 to 6 mi-
nutes before being decreased to 2% for 2.5 minutes. 2 μl of the samples
were injected.
The electrospray source was operated in positive ionization mode
(ESIþ). The source conditions were optimized using the Source Opti-
mizer software included in the MassHunter software package (Agilent
Technologies, Waldbronn, Germany). The capillary voltage was set at
1500 V. Nitrogen was used as dry gas and sheath gas heated at 210 C
with a ﬂow rate of 17 L/min and 400 C at 12 L/min, respectively. The
nebulizer pressure was settled at 55 psi. The high pressure and low-
pressure funnels were operated at 150 and 100 V. Fragmentation and
collision energies were optimized for each analyte using the Optimizer
software. Unit mass resolution was set in both mass-resolving quadru-
poles Q1 and Q3. Cell accelerator voltage was kept at 4 V. Analyses were
conducted in dynamic multiple reaction monitoring (dMRM) mode. Two
transitions were followed for thiochrome, BFT and S-BT. The monitored
transitions were m/z 263 → 231 (quantiﬁer) and m/z 263 → 198
(qualiﬁer) for thiochrome, m/z 467 → 122 (quantiﬁer) and m/z 467 →
105 (qualiﬁer) for BFT and m/z 387 → 122 (quantiﬁer) and m/z 387 →
104 (qualiﬁer) for S-BT.
Samples were prepared as described in paragraph 4.3. Calibration
curves were done using thiochrome, BFT, S-BT standards at 1 μM, 5 μM,
10 μM, 50 μM and 100 μM prepared in thiamine-free medium with 10 %
of FBS. 20 μl of TCA was added to 100 μl of the standard mix. It was
vortexed for 20 s and centrifuged for 15 min. The supernatant was
collected and washed with ether three times to remove TCA.
Both samples and standards for calibration curves were diluted 1000
times with H2O þ 0.1% formic acid. 50 μL of sample were loaded on
Ostro 96 well plates (Waters, Dublin, Ireland) andmixed with 150 μl ACN
þ 1% formic acid. Samples were passed through the plate and extracts
were vacuum-dried at 30 C for 90 minutes using a CentriVap Concen-
trator (LabConco, Kansas-City, MO, USA). Samples were eventually
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